Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.615 AUD -3.58% Market Closed
Market Cap: 2.1B AUD

EV/EBIT
Enterprise Value to EBIT

-17.8
Current
-12.1
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-17.8
=
Enterprise Value
2.2B AUD
/
EBIT
-80.2m USD
EBIT Growth EV/EBIT to Growth
AU
Mesoblast Ltd
ASX:MSB
Average EV/EBIT: 20.3
Negative Multiple: -17.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 797.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361.5 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-21.6
2-Years Forward
EV/EBIT
-33
3-Years Forward
EV/EBIT
14.3